2024
Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Chow R, Celio L, Im J, Caini S, Eng L, Prsic E, Scotté F, Aapro M. Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Supportive Care In Cancer 2024, 32: 736. PMID: 39432169, DOI: 10.1007/s00520-024-08934-0.Peer-Reviewed Original ResearchConceptsDexamethasone-sparing regimenChemotherapy-induced nausea and vomitingModerately emetogenic chemotherapyHighly emetogenic chemotherapyRandomized controlled trialsComplete responseMeta-analysisEmetogenic chemotherapyNo vomitingRescue medicationProphylaxis of chemotherapy-induced nausea and vomitingSystematic reviewSchedule of dexamethasoneNausea and vomitingChemotherapy-induced nauseaResultsTen trialsAntiemetic regimenCumulative meta-analysisEffect estimatesSafety profileComprehensive systematic reviewMethodsOvid MEDLINERegimensAdult cancer patientsCancer patients
2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Supportive & Palliative Care 2022, 13: 27-34. PMID: 36194493, DOI: 10.1136/spcare-2022-003815.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyTreatment of CIPNDuloxetine usePeripheral neuropathyRisk ratioPrevention of CIPNSystematic reviewUse of duloxetineSummary risk ratiosClinical practice recommendationsHigh-quality trialsDerSimonian-Laird modelComprehensive systematic reviewCochrane CENTRALSafety profileDatabase inceptionHuman trialsDuloxetinePractice recommendationsLimited evidencePreventionTrialsNeuropathyTreatmentReview